[go: up one dir, main page]

WO2010073011A3 - Composés utiles comme médicaments - Google Patents

Composés utiles comme médicaments Download PDF

Info

Publication number
WO2010073011A3
WO2010073011A3 PCT/GB2009/002945 GB2009002945W WO2010073011A3 WO 2010073011 A3 WO2010073011 A3 WO 2010073011A3 GB 2009002945 W GB2009002945 W GB 2009002945W WO 2010073011 A3 WO2010073011 A3 WO 2010073011A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compounds
ampk activators
ampk
compounds
cardioprotection
Prior art date
Application number
PCT/GB2009/002945
Other languages
English (en)
Other versions
WO2010073011A2 (fr
Inventor
Jacob Westman
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of WO2010073011A2 publication Critical patent/WO2010073011A2/fr
Publication of WO2010073011A3 publication Critical patent/WO2010073011A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La présente invention concerne des composés de formule I dans laquelle les lignes pointillées, X, T, G, N, Y, A1 à A5 et D1 à D5 prennent les significations données dans la description. Ces composés sont utiles dans le traitement d'états ou de troubles améliorés par l'activation de l'AMPK, par exemple les maladies de la peau, les maladies pulmonaires, l'obésité, la dégénérescence maculaire liée à l'âge de type sec, la cardioprotection ou, de préférence, l'hyperinsulinémie, le diabète, le cancer, la fibrose, les maladies neurodégénératives, les dysfonctionnements sexuels, l'insuffisance cardiaque, l'inflammation et l'ostéoporose.
PCT/GB2009/002945 2008-12-23 2009-12-22 Composés utiles comme médicaments WO2010073011A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US19377408P 2008-12-23 2008-12-23
US61/193,774 2008-12-23
US20208409P 2009-01-27 2009-01-27
US61/202,084 2009-01-27
US20287909P 2009-04-15 2009-04-15
US61/202,879 2009-04-15
US24146309P 2009-09-11 2009-09-11
US61/241,463 2009-09-11

Publications (2)

Publication Number Publication Date
WO2010073011A2 WO2010073011A2 (fr) 2010-07-01
WO2010073011A3 true WO2010073011A3 (fr) 2010-09-23

Family

ID=42061073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002945 WO2010073011A2 (fr) 2008-12-23 2009-12-22 Composés utiles comme médicaments

Country Status (1)

Country Link
WO (1) WO2010073011A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN108578682B (zh) * 2018-07-13 2022-04-12 浙江省医学科学院 艾塞那肽在制备用于治疗肺纤维化的药物中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003467A2 (fr) * 2011-06-27 2013-01-03 Massachusetts Eye And Ear Infirmary Procédés de traitement de troubles inflammatoires oculaires
EP2755652B1 (fr) 2011-09-16 2021-06-02 Novartis AG Hétérocyclyle carboxamides n-substitués
CN103467417B (zh) * 2012-06-07 2015-05-20 中国科学院上海药物研究所 牛蒡子苷元碳酰胺衍生物及其制备方法、包含该衍生物的组合物、及其用途
US8877980B2 (en) * 2012-09-11 2014-11-04 Al-Urdonia Lemudaddat Al-Ajsam Co. Phenylboronic acid
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
CA2905242C (fr) 2013-03-15 2016-11-29 Pfizer Inc. Composes indoliques activant l'ampk
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
CN106414429B (zh) 2014-06-03 2020-01-03 爱杜西亚药品有限公司 吡唑化合物及其作为t型钙通道阻断剂的用途
CA2956816C (fr) 2014-09-15 2023-02-14 Actelion Pharmaceuticals Ltd Composes triazole utilises comme bloqueurs des canaux calciques de type t
JP6938510B2 (ja) 2015-12-24 2021-09-22 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
EP3394083B9 (fr) * 2015-12-24 2022-04-27 The Regents of the University of California Dérivés de n-[5-[(3,4-diméthoxyphenyl)méthyl]-1,3,4-thiadiazol-2-yl]-2-méthoxy-benzeneacétamide et composés similaires en tant qu'activateurs cftr pour le traitement de constipation ou cholestasis
JP6755778B2 (ja) * 2016-11-11 2020-09-16 花王株式会社 ＰＰＡＲα活性化剤
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
WO2019040919A1 (fr) 2017-08-24 2019-02-28 The Regents Of The University Of California Compositions pharmaceutiques oculaires
WO2019070709A1 (fr) * 2017-10-02 2019-04-11 The Regents Of The University Of California Composés pour le traitement ou la prévention d'infections à flavivirus
AU2020380926A1 (en) * 2019-11-05 2022-05-26 Dermira, Inc. MrgprX2 antagonists and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103980A1 (fr) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i
WO2005085220A1 (fr) * 2004-02-26 2005-09-15 Merck Patent Gmbh Utilisation de derives de thiadiazole-uree
WO2007002461A1 (fr) * 2005-06-23 2007-01-04 Dr. Reddy's Laboratories Ltd. Thiazoles substitués en 3,4 en tant qu'activateurs de l'ampk
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2511371A (en) 1945-03-12 1950-06-13 Monsanto Chemicals Sulfa derivatives of 2-amino-5-alkenyl-1, 3, 4-thiadiazoles
US2420434A (en) 1945-03-12 1947-05-13 Monsanto Chemicals 2-amino-5-alkenyl-1, 3, 4 thiadiazoles and process for making the same
US2524729A (en) 1945-03-12 1950-10-03 Monsanto Chemicals 2-amino-5-benzyl-1, 3, 4-thiadiazole and acid salts thereof
US3720685A (en) 1970-07-15 1973-03-13 Squibb & Sons Inc 3-amino-5-benzyl-1,2,4-oxadiazoles
US4054665A (en) 1974-11-29 1977-10-18 Sandoz, Inc. 2-Amino-5-(trifluoromethylphenylalkyl)-1,3,4 thiadiazoles used in the treatment of insomnia and anxiety
CH602685A5 (fr) 1975-12-01 1978-07-31 Merck Patent Gmbh
DE2611965A1 (de) 1976-03-20 1977-09-29 Merck Patent Gmbh Verfahren zur herstellung von 1,3,4- thiadiazol-5-thiolen
JP3258771B2 (ja) 1992-11-16 2002-02-18 株式会社豊田製作所 ブレーキロータの面振れ測定用治具
EP1545523A1 (fr) 2002-07-03 2005-06-29 Astex Technology Limited 3-(hetero) arylmethoxy pyridines et leurs analogues en tant qu'inhibiteurs de la p38 map kinase
US7262020B2 (en) 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2005002673A1 (fr) 2003-07-03 2005-01-13 Astex Therapeutics Limited Inhibiteurs de raf kinase
CA2610196A1 (fr) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
JP2009501775A (ja) 2005-07-21 2009-01-22 ベタゲノン・エイビー 癌治療におけるチアゾール誘導体およびアナログの使用
US7754773B2 (en) 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
WO2008029266A1 (fr) 2006-09-08 2008-03-13 Glenmark Pharmaceuticals S.A. Inhibiteurs de la stéaroyl coa désaturase
WO2008062276A2 (fr) 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Dérivés d'acétylène comme inhibiteurs de la stéaroyl coa désaturase
US20100120669A1 (en) 2007-02-28 2010-05-13 Anne Marie Jeanne Bouillot Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103980A1 (fr) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i
WO2005085220A1 (fr) * 2004-02-26 2005-09-15 Merck Patent Gmbh Utilisation de derives de thiadiazole-uree
WO2007002461A1 (fr) * 2005-06-23 2007-01-04 Dr. Reddy's Laboratories Ltd. Thiazoles substitués en 3,4 en tant qu'activateurs de l'ampk
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2009, GOLDFARB, DAVID SCOTT: "Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds", XP002593929, retrieved from STN Database accession no. 2009:846107 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN108578682B (zh) * 2018-07-13 2022-04-12 浙江省医学科学院 艾塞那肽在制备用于治疗肺纤维化的药物中的应用

Also Published As

Publication number Publication date
WO2010073011A2 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010073011A3 (fr) Composés utiles comme médicaments
WO2009111700A3 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2010114824A8 (fr) Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation
WO2009063202A3 (fr) Utilisation de composés antagonistes de crth2
WO2011028947A3 (fr) Composés hétérocycliques pour l'inhibition de la pask
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
MY156530A (en) Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators
EP1937633B8 (fr) Derives d'acide biphenyloxyacetique utilises pour le traitement de maladies respiratoires
WO2009155527A3 (fr) Inhibiteurs de phosphatidylinositol 3 kinase
WO2012149157A3 (fr) Composés hétérocycliques pour l'inhibition de pask
WO2011044506A3 (fr) Composés sulfonés et leurs procédés de fabrication et d'utilisation
WO2008091540A3 (fr) Modulateurs de tgr5 et leurs procédés d'utilisation
TNSN07431A1 (en) Imidazoquinolines as lipid kinase inhibitors
WO2010141796A3 (fr) Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
WO2010080756A3 (fr) Dérivés d'harmine pour réduire la masse corporelle
WO2009120660A3 (fr) Pyridoxazines substituées
EP2826472A3 (fr) Composés d'activation de la télomérase et leur utilisation
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2007009723A3 (fr) Derives de pyrazoline substitues azepane ou azocane, fabrication et utilisation comme medicaments
WO2012119046A3 (fr) Composés hétérocycliques pour l'inhibition de la kinase de domaine pas (pask)
WO2008010061A3 (fr) 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation
EA200870074A1 (ru) Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
WO2011028737A3 (fr) Compositions de bisphosphonate et procédés de traitement d'une insuffisance cardiaque
WO2008152068A3 (fr) Dérivés de [1,10]-phénanthroline pour le traitement de maladies neurodégénératives ou hématologiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801242

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09801242

Country of ref document: EP

Kind code of ref document: A2